Drug Profile
Research programme: small molecule therapeutics - Bayer/X-Chem
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Bayer; X-Chem
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Undefined in USA
- 03 Oct 2017 X-Chem and Bayer further expand small molecule therapeutics discovery collaboration for multiple indications
- 12 Jul 2016 X-Chem and Bayer expand small molecule therapeutics discovery collaboration worldwide for multiple indications